본문으로 건너뛰기
← 뒤로

Improved overall survival in acute myeloid leukemia over the last 15 years.

1/5 보강
Leukemia & lymphoma 📖 저널 OA 8.2% 2022: 1/1 OA 2025: 2/55 OA 2026: 13/137 OA 2022~2026 2026 p. 1-9
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
895 patients aged ≥ 18 years, divided into three diagnosis eras: 2004-2010, 2011-2016, and 2017-2019.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our findings demonstrate that survival has improved significantly, coinciding with the introduction of venetoclax-based regimens and targeted therapies for FLT3 and IDH1/2 mutations, although disparities by socioeconomic factors persist.

Simkhada S, Acharya L, Loeffler B, Ravindra A, Pyakuryal A, Parajuli S, Bhatt VR, Dhakal P

📝 환자 설명용 한 줄

This study evaluated changes in overall survival (OS) among patients diagnosed with AML from 2004 to 2019 using the National Cancer Database.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Simkhada S, Acharya L, et al. (2026). Improved overall survival in acute myeloid leukemia over the last 15 years.. Leukemia & lymphoma, 1-9. https://doi.org/10.1080/10428194.2026.2635662
MLA Simkhada S, et al.. "Improved overall survival in acute myeloid leukemia over the last 15 years.." Leukemia & lymphoma, 2026, pp. 1-9.
PMID 41793418 ↗

Abstract

This study evaluated changes in overall survival (OS) among patients diagnosed with AML from 2004 to 2019 using the National Cancer Database. The analysis included 67,895 patients aged ≥ 18 years, divided into three diagnosis eras: 2004-2010, 2011-2016, and 2017-2019. Median OS steadily improved over time: 7.6 months in 2004-2010, 8.6 months in 2011-2016, and 10.4 months in 2017-2019. The impact of age, AML subtype, chemotherapy, and HCT on OS changed over time, especially showing a stronger positive association with chemotherapy and HCT after 2017. OS remained lower in males, non-Hispanics, racial groups other than Black or White, individuals with a CCI> 0, those with public or no insurance, and those with an annual income <$35000. Our findings demonstrate that survival has improved significantly, coinciding with the introduction of venetoclax-based regimens and targeted therapies for FLT3 and IDH1/2 mutations, although disparities by socioeconomic factors persist.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반